New YouTube Policy Targets Cancer Misinformation
Online misinformation is harming cancer patients. YouTube has been part of the problem, but a new policy might change that.
Lung Cancers News
LUNG CANCER ADVISOR
Lung Cancers News
OSE2101 Vaccine Outperforms Standard Care in Certain Patients With NSCLC
The cancer vaccine OSE2101 improved survival in patients with HLA-A2+, advanced NSCLC and secondary resistance to ICIs in a phase 3 trial.
Radiotherapy for Prostate Cancer Linked to Higher Risk of Bladder and Lung Cancer
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
Cisplatin Shortage Nearly Resolved; Supplies of Carboplatin, Methotrexate Increasing
The US supply of cisplatin is nearly restored, and shortages of carboplatin and methotrexate have been alleviated, the government says.
Ranitidine Does Not Increase the Risk of Cancer, Study Suggests
A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.
Oncologists Receive More EHR Messages Than Other HCPs but Spend Less Time in EHRs
A new study suggests that electronic health records could be better tailored to meet the specific needs of oncologists.
Identifying Prognostic Factors in Pleural Mesothelioma
Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Cardiovascular Events After ICI Therapy “Common” in Lung Cancer
Cardiovascular toxicity related to immune checkpoint inhibitor therapy is “common” in patients with lung cancer, a new study suggests.
Cancer Deaths Increased During the First 2 Years of the COVID-19 Pandemic
Cancer deaths increased during the first 2 years of the COVID-19 pandemic in the United States, a population-based study suggests.
COVID-19 Vaccines Increase PD-L1 Levels, Might Reverse Treatment Resistance in NSCLC
New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.
Adding Nivolumab to SABR Improves EFS in NSCLC
Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.
Breakthroughs in Targeted Therapy, Immunotherapy Reduce Cancer Deaths
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Can a Breath Test Detect Mesothelioma? It’s Too Soon to Tell.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
Eliminating H2RAs From Paclitaxel Premedication Does Not Increase Infusion Reactions
The use of H2RAs to prevent infusion-related reactions to paclitaxel should be reevaluated, according to researchers.
Tepotinib Plus Osimertinib May Provide Chemo-Free Option for NSCLC After First-Line Osimertinib
Tepotinib plus osimertinib has demonstrated efficacy in advanced, EGFR-mutant, MET-amplified NSCLC that progressed on first-line osimertinib.
Lung Cancer Patients Have High Burden of COVID-19 Death in Omicron Era
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Perioperative Durvalumab Does Not Impact Surgical Outcomes in NSCLC
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
Adding Serplulimab to Chemotherapy Improves Survival in Squamous NSCLC
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
First-Line Benmelstobart Regimen Produces Longest PFS, OS to Date in ES-SCLC
Adding benmelstobart and anlotinib to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with ES-SCLC.
Adagrasib Shows “Durable Clinical Benefit” in Advanced KRAS-Mutant NSCLC
Adagrasib has shown durable clinical activity in patients with advanced KRASG12C-mutant NSCLC, according to updated results from the KRYSTAL-1 trial.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lung Cancer News
Loading... 
Loading...